| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2024 ( Subtotal = $0 ) |
| | 2024 | 2023 | EITR BIOLOGICS, INC. | 7090 MIRATECH DR STE 130 | SAN DIEGO | CA | 92121-3109 | SAN DIEGO | USA | R44AI177179 | Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure | 001 | 1 | NIH | 4/3/2024 | $0 |
| | 2024 | 2023 | EITR BIOLOGICS, INC. | 7090 MIRATECH DR STE 130 | SAN DIEGO | CA | 92121-3109 | SAN DIEGO | USA | R43IP001224 | PA-22-176, SBIR, Phase I, Novel Bispecific Nanotherapeutics as Broad-Spectrum Influenza Antivirals Refractory to Viral Escape | 01 | 1 | CDC | 12/15/2023 | $0 |
| | 2024 | 2023 | EITR BIOLOGICS, INC. | 7090 MIRATECH DR STE 130 | SAN DIEGO | CA | 92121-3109 | SAN DIEGO | USA | R43IP001224 | PA-22-176, SBIR, Phase I, Novel Bispecific Nanotherapeutics as Broad-Spectrum Influenza Antivirals Refractory to Viral Escape | 03 | 1 | CDC | 9/17/2024 | $0 |
| | 2024 | 2023 | EITR BIOLOGICS, INC. | 7090 MIRATECH DR STE 130 | SAN DIEGO | CA | 92121-3109 | SAN DIEGO | USA | R43IP001224 | PA-22-176, SBIR, Phase I, Novel Bispecific Nanotherapeutics as Broad-Spectrum Influenza Antivirals Refractory to Viral Escape | 02 | 1 | CDC | 2/15/2024 | $0 |
| | 2024 | 2023 | EITR BIOLOGICS, INC. | 7090 MIRATECH DR STE 130 | SAN DIEGO | CA | 92121-3109 | SAN DIEGO | USA | R44AI177179 | Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure | 000 | 1 | NIH | 2/29/2024 | $0 |
|
| Issue Date FY: 2023 ( Subtotal = $583,346 ) |
| | 2023 | 2023 | EITR BIOLOGICS, INC. | 6555 NANCY RIDGE DR STE 300 | SAN DIEGO | CA | 92121-3221 | SAN DIEGO | USA | R44AI177179 | Multidimensional antibody engineering to enhance the potency and breadth of a betacoronavirus medical countermeasure | 000 | 1 | NIH | 6/26/2023 | $283,552 |
| | 2023 | 2023 | EITR BIOLOGICS, INC. | 7090 MIRATECH DR STE 130 | SAN DIEGO | CA | 92121-3109 | SAN DIEGO | USA | R43IP001224 | PA-22-176, SBIR, Phase I, Novel Bispecific Nanotherapeutics as Broad-Spectrum Influenza Antivirals Refractory to Viral Escape | 00 | 1 | CDC | 8/24/2023 | $299,794 |
|
|
